Olema Pharmaceuticals (OLMA): Price and Financial Metrics
GET POWR RATINGS... FREE!
OLMA Stock Price Chart Interactive Chart >
OLMA Price/Volume Stats
| Current price | $2.95 | 52-week high | $32.77 |
| Prev. close | $2.81 | 52-week low | $2.00 |
| Day low | $2.73 | Volume | 272,108 |
| Day high | $3.00 | Avg. volume | 417,374 |
| 50-day MA | $3.19 | Dividend yield | N/A |
| 200-day MA | $13.75 | Market Cap | 119.04M |
Olema Pharmaceuticals (OLMA) Company Bio
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Latest OLMA News From Around the Web
Below are the latest news stories about Olema Pharmaceuticals Inc that investors may wish to consider to help them evaluate OLMA as an investment opportunity.
Olema Oncology to Present at Cowen 42nd Annual Health Care ConferenceSAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 2:50 p.m. ET (11:50 a.m. PT). A live webcast of the presentation may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be arch |
We're Hopeful That Olema Pharmaceuticals (NASDAQ:OLMA) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Olema reports inducement grants of 270K stock optionsOlema Pharmaceuticals (OLMA) granted stock options to two new employees to buy a total 270K common shares under the company''s 2022 Inducement Plan.The company''s new Chief Medical |
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to two new employees to purchase an aggregate of 270,000 shares of the Company's common stock, effective as of February 1, 2022. An option to purchase 250,000 sh |
Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer• Dr. Zojwalla brings extensive and diverse experience in clinical development and regulatory strategy for novel oncology therapies • As part of planned leadership transition, former CMO Pamela Klein, M.D., will become a senior advisor and member of Olema’s Scientific Advisory Board SAN FRANCISCO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commerci |
OLMA Price Returns
| 1-mo | 7.66% |
| 3-mo | -35.87% |
| 6-mo | -85.86% |
| 1-year | -89.57% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -68.48% |
| 2021 | -80.53% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...